Wikipedia -WSS

Wikipedia

author：explore 2025-10-02 00:40:27 - browse：12539

A gene therapy study, halted when four children with a rare neuromuscular disorder died after treatment, showed enough promise to merit finding a path forward, according to the medicine’s manufacturer.

The treatment, made by the Japanese pharmaceutical company Astellas, led to severe and fatal liver problems for four of the 24 treated children with X-linked myotubular myopathy, or XLMTM, a genetic disease that severely degrades muscle function and kills most patients before the age of 10. Three died in 2020; the fourth died a year later.

In an analysis of its clinical trial, published in Lancet Neurology on Wednesday, Astellas observed dramatic benefits in the study’s surviving patients and a potential explanation for the deaths that derailed the trial. The hope, for Astellas and for families affected by XLMTM, is that the company can find a safe way to proceed and convince the Food and Drug Administration to allow it to resume development.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Empower primary care with adequate payments and technology

WSS

The effects of a landmark ruling on DNA ownership are becoming clearer

Insmed lung disease drug hits target in key Phase 3 trial

HHS's proposed rule does nothing to address the climate crisis

The creative science of coining drug names

GSK’s asthma push continues as drug succeeds in Phase 3 trials

AltruBio raises $225 million to develop ulcerative colitis drug

hotspot

Wikipedia

focus

Duchenne breakthrough therapy leaves behind pioneering families

Brain technologies pose threats that are all too real, experts warn

How to save PrEP access — and even expand it

Most antidepressants don't work on kids, teens, study finds

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

HHS's proposed rule does nothing to address the climate crisis

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

AI used to predict Covid

Walensky prepares to leave CDC — and Congress — behind

Lab trade group sues FDA to halt regulation of lab

entertainment

Health insurers say they are turning to AI to cut costs, improve care

BIO to announce reorganization, senior leaders expected to depart

Welsh Carson private equity firm escapes from FTC antitrust case

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Biohaven protein

Heat waves linked to early deliveries, preterm births in new study

hotspot

explore

leisure time

leisure time